We have located links that may give you full text access.
Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it identify blastemal predominance?
PURPOSE: To explore the potential relation between whole-tumor apparent diffusion coefficient (ADC) parameters in viable parts of tumor and histopathological findings in nephroblastoma.
MATERIALS AND METHODS: Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before resection. An experienced reader performed the whole-tumor ADC measurements of all lesions, excluding nonenhancing areas. An experienced pathologist reviewed the postoperative specimens according to standard SIOP guidelines. Potential associations between ADC parameters and proportions of histological subtypes were assessed with Pearson's or Spearman's rank correlation coefficient depending on whether the parameters tested were normally distributed. In case the Mann-Whitney U-test revealed significantly different ADC values in a subtype tumor, this ADC parameter was used to derive a receiver operating characteristic (ROC) curve.
RESULTS: The 25th percentile ADC at presentation was the best ADC metric correlated with proportion of blastema (Pearson's r = -0.303, P = 0.026). ADC after preoperative treatment showed moderate correlation with proportion stromal subtype at histopathology (r = 0.579, P = 0.002). By ROC analysis, the optimal threshold of median ADC for detecting stromal subtype was 1.362 × 10-3 mm2 /s with sensitivity and specificity of 100% (95% confidence interval [CI] 0.65-1.00) and 78.9% (95% CI 0.57-0.92), respectively.
CONCLUSION: ADC markers in nephroblastoma are related to stromal subtype histopathology; however, identification of blastemal predominant tumors using whole-tumor ADC measurements is probably not feasible.
LEVEL OF EVIDENCE: 3 J. MAGN. RESON. IMAGING 2017;45:1316-1324.
MATERIALS AND METHODS: Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before resection. An experienced reader performed the whole-tumor ADC measurements of all lesions, excluding nonenhancing areas. An experienced pathologist reviewed the postoperative specimens according to standard SIOP guidelines. Potential associations between ADC parameters and proportions of histological subtypes were assessed with Pearson's or Spearman's rank correlation coefficient depending on whether the parameters tested were normally distributed. In case the Mann-Whitney U-test revealed significantly different ADC values in a subtype tumor, this ADC parameter was used to derive a receiver operating characteristic (ROC) curve.
RESULTS: The 25th percentile ADC at presentation was the best ADC metric correlated with proportion of blastema (Pearson's r = -0.303, P = 0.026). ADC after preoperative treatment showed moderate correlation with proportion stromal subtype at histopathology (r = 0.579, P = 0.002). By ROC analysis, the optimal threshold of median ADC for detecting stromal subtype was 1.362 × 10-3 mm2 /s with sensitivity and specificity of 100% (95% confidence interval [CI] 0.65-1.00) and 78.9% (95% CI 0.57-0.92), respectively.
CONCLUSION: ADC markers in nephroblastoma are related to stromal subtype histopathology; however, identification of blastemal predominant tumors using whole-tumor ADC measurements is probably not feasible.
LEVEL OF EVIDENCE: 3 J. MAGN. RESON. IMAGING 2017;45:1316-1324.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app